Altimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). Please contact us for more information
Our management team has broad expertise across scientific and business operations, inventing compounds and advancing product candidates through clinical development.
Board of Directors
We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Jose Ochoa, Chief Business Officer, for partnership inquiries.
For partnership opportunities contact:
Chief Business Officer